Icon Group says almost 30 per cent of global oncology clinical trials remain suspended as a result of the COVID-19 pandemic with ongoing uncertainty of the full impact on drug development and treatment.
Icon Group says it is Australia's largest dedicated provider of cancer care and remains focused on expanding its trial capacity.
The company said it has appointed Joanne Chio as its first Singapore-based clinical trials director and that it anticipates increased collaboration with clinicians and research teams in Australia.
“This is an important step in the continued evolution of our clinical trials offering which comes at a critical time given the impact of the pandemic. It will bolster our ability to provide a holistic approach to treatment and deliver the best care possible to cancer patients in Singapore and across the ASEAN region,” said Sophie Mepham, Icon Group executive manager of research.
Icon Group first entered the Singapore market in 2016 through the acquisition of Singapore Oncology Consultants. It was renamed Icon Cancer Centre.
The company said that in the past two years it has also brought on a dedicated health screening clinic, a Young Women’s Cancer Program and paediatric oncology services. It will open the new Mt Alvernia comprehensive Icon Cancer Centre set to open in 2022.